Early reduction in circulating tumor DNA (ctDNA) and survival in gastric cancer patients (pts) treated with durvalumab (D), tremelimumab (T), or durvalumab in combination with tremelimumab (D plus T)-MedSci.cn

Early reduction in circulating tumor DNA (ctDNA) and survival in gastric cancer patients (pts) treated with durvalumab (D), tremelimumab (T), or durvalumab in combination with tremelimumab (D plus T)

Brohawn, PZ; Higgs, BW; Kuziora, M; Englert, J; Ranade, K

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (15):

科室
- - 订阅+
  - 更多科室
工具
服务